Role of NLRP3 Inflammasome in Chronic Pain and Alzheimer's Disease-A Review
- PMID: 39853846
- PMCID: PMC11798427
- DOI: 10.1002/jbt.70071
Role of NLRP3 Inflammasome in Chronic Pain and Alzheimer's Disease-A Review
Abstract
The coexistence of Alzheimer's disease (AD) and chronic pain (CP) in the elderly population has been extensively documented, and a growing body of evidence supports the potential interconnections between these two conditions. This comprehensive review explores the mechanisms by which CP may contribute to the development and progression of AD, with a particular focus on neuroinflammatory pathways and the role of microglia, as well as the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome. The review proposes that prolonged pain processing in critical brain regions can dysregulate the activity of the NLRP3 inflammasome within microglia, leading to the overproduction of pro-inflammatory cytokines and excessive oxidative stress in these regions. This aberrant microglial response also results in localized neuroinflammation in brain areas crucial for cognitive function. Additionally, CP as a persistent physiological and psychological stressor may be associated with hypothalamic-pituitary-adrenal (HPA) axis dysfunction, systemic inflammation, disruption of the blood-brain barrier (BBB), and neuroinflammation. These pathophysiological changes can cause morphological and functional impairments in brain regions responsible for cognition, memory, and neurotransmitter production, potentially contributing to the development and progression of CP-associated AD. Resultant neuroinflammation can further promote amyloid-beta (Aβ) plaque deposition, a hallmark of AD pathology. Potential therapeutic interventions targeting these neuroinflammatory pathways, particularly through the regulation of microglial NLRP3 activation, hold promise for improving outcomes in individuals with comorbid CP and AD. However, further research is required to fully elucidate the complex interplay between these conditions and develop effective treatment strategies.
Keywords: Alzheimer's disease; NLRP3; chronic pain; microglia; neuroinflammation.
© 2025 Wiley Periodicals LLC.
Conflict of interest statement
Similar articles
-
Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.CNS Neurosci Ther. 2018 Dec;24(12):1207-1218. doi: 10.1111/cns.12983. Epub 2018 Jun 4. CNS Neurosci Ther. 2018. PMID: 29869390 Free PMC article.
-
Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer's Disease.Neurochem Res. 2020 Nov;45(11):2560-2572. doi: 10.1007/s11064-020-03121-z. Epub 2020 Sep 14. Neurochem Res. 2020. PMID: 32929691 Review.
-
Inflammasome-Mediated Neuroinflammation: A Key Driver in Alzheimer's Disease Pathogenesis.Biomolecules. 2025 May 7;15(5):676. doi: 10.3390/biom15050676. Biomolecules. 2025. PMID: 40427569 Free PMC article. Review.
-
Exerkines mitigating Alzheimer's disease progression by regulating inflammation: Focusing on macrophage/microglial NLRP3 inflammasome pathway.Alzheimers Dement. 2025 Feb;21(2):e14432. doi: 10.1002/alz.14432. Epub 2024 Dec 6. Alzheimers Dement. 2025. PMID: 39641407 Free PMC article. Review.
-
Microglial NLRP3 Inflammasomes in Alzheimer's Disease Pathogenesis: From Interaction with Autophagy/Mitophagy to Therapeutics.Mol Neurobiol. 2025 Jun;62(6):7124-7143. doi: 10.1007/s12035-025-04758-z. Epub 2025 Feb 14. Mol Neurobiol. 2025. PMID: 39951189 Review.
References
-
- Blank RH. Social & Public Policy of Alzheimer’s Disease in the United States: Springer; 2018.
-
- Jakobsson U, Klevsgård R, Westergren A, Hallberg IR. Old people in pain: a comparative study. Journal of pain and symptom management. 2003;26(1):625–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous